| human | Q5 |
| P2798 | Loop ID | 75676 |
| P496 | ORCID iD | 0000-0003-1003-5138 |
| P2038 | ResearchGate profile ID | Gerard_Hanna |
| P1153 | Scopus author ID | 23492187200 |
| P69 | educated at | Queen's University Belfast | Q877925 |
| P108 | employer | Belfast Health and Social Care Trust | Q4882291 |
| Queen's University Belfast | Q877925 | ||
| Peter MacCallum Cancer Centre | Q7175569 | ||
| P734 | family name | Hanna | Q15729071 |
| Hanna | Q15729071 | ||
| Hanna | Q15729071 | ||
| P735 | given name | Gerard | Q1261347 |
| Gerard | Q1261347 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q43295889 | (18)F-FDG PET-CT simulation for non-small-cell lung cancer: effect in patients already staged by PET-CT. |
| Q43115647 | 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiotherapy target volume definition in non-small-cell lung cancer: delineation by radiation oncologists vs. joint outlining with a PET radiologist? |
| Q80722392 | A case of prolonged type 1 hypersensitivity reaction to pegfilgrastim |
| Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
| Q89124987 | An overview on personalisation of radiotherapy prescriptions in locally advanced non-small cell lung cancer: Are we there yet? |
| Q100728610 | CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer |
| Q52579899 | CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. |
| Q59587390 | Defining Target Volumes for Stereotactic Ablative Radiotherapy of Early-stage Lung Tumours: A Comparison of Three-dimensional 18F-fluorodeoxyglucose Positron Emission Tomography and Four-dimensional Computed Tomography |
| Q92222918 | Differential Relapse Patterns for Non-small Cell Lung Cancer Subtypes Adenocarcinoma and Squamous Cell Carcinoma: Implications for Radiation Oncology |
| Q88332526 | Do protons have a role in the treatment of locally advanced NSCLC with radiotherapy? |
| Q38754740 | FLIP: A Targetable Mediator of Resistance to Radiation in Non-Small Cell Lung Cancer. |
| Q33606505 | Geometrical analysis of radiotherapy target volume delineation: a systematic review of reported comparison methods. |
| Q38429240 | Immune modulation in advanced radiotherapies: Targeting out-of-field effects |
| Q37767027 | Improving target delineation on 4-dimensional CT scans in stage I NSCLC using a deformable registration tool. |
| Q85635193 | In Regard to Vaidya et al |
| Q38697545 | Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy. |
| Q36235523 | Intraoperative radiotherapy in early stage breast cancer: potential indications and evidence to date |
| Q51133431 | Investigating the potential impact of four-dimensional computed tomography (4DCT) on toxicity, outcomes and dose escalation for radical lung cancer radiotherapy. |
| Q94559352 | Learning radiotherapy: the state of the art |
| Q38167438 | Motion management for radical radiotherapy in non-small cell lung cancer. |
| Q48763632 | Multiple training interventions significantly improve reproducibility of PET/CT-based lung cancer radiotherapy target volume delineation using an IAEA study protocol |
| Q30392150 | Optimizing geometric accuracy of four-dimensional CT scans acquired using the wall- and couch-mounted Varian® Real-time Position Management™ camera systems |
| Q100995500 | PET/CT features of lung SABR chest wall toxicity |
| Q38419113 | PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. |
| Q99715552 | Particle Therapy in Australia: iacta alea est! |
| Q91750469 | Particle therapy tumour outcomes: An updated systematic review |
| Q58576082 | Predicting Outcomes From Radical Radiotherapy for Non-small Cell Lung Cancer: A Systematic Review of the Existing Literature |
| Q87416333 | Preoperative chemotherapy for non-small-cell lung cancer |
| Q36818897 | Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. |
| Q90752563 | Radiation oncology trainee research requirements - re-thinking our intention and approach |
| Q38831848 | Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future? |
| Q37353925 | Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer. |
| Q49976711 | Re-irradiation for Locally Recurrent Lung Cancer: Evidence, Risks and Benefits. |
| Q85531728 | Re: Stereotactic Body Radiotherapy for Oligometastatic Disease |
| Q88083181 | Referrals Patterns to an Oncology Clinical Advice Service |
| Q91367008 | Risk of Death from Pneumocystis jirovecii after Curative-intent Radiotherapy for Lung Cancer |
| Q104281068 | Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer |
| Q46165932 | Standardization of scanning for [18F]fluorodeoxyglucose positron emission tomography |
| Q38377495 | Stereotactic body radiotherapy for oligometastatic disease. |
| Q52582229 | Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung c |
| Q99409878 | Survey of clinician opinions on the role of proton beam therapy in Australia and New Zealand |
| Q90039281 | The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado? |
| Q38945410 | The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer. |
| Q47314874 | The Elderly are Less Likely to Receive Recommended Radical Radiotherapy for Non-small Cell Lung Cancer. |
| Q38543483 | The Impact of Colleague Peer Review on the Radiotherapy Treatment Planning Process in the Radical Treatment of Lung Cancer |
| Q37131297 | The mediastinal staging accuracy of 18F-Fluorodeoxyglycose positron emission tomography/computed tomography in non-small cell lung cancer with variable time intervals to surgery |
| Q88407400 | Thoracic intervention and surgery to cure lung cancer: an overview of stereotactic ablative radiotherapy in early and oligometastatic lung cancer |
| Q59793133 | Towards photon radiotherapy treatment planning with high Z nanoparticle radiosensitisation agents: the Relative Biological Effective Dose (RBED) framework |
| Q42697004 | UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. |
| Q52801973 | UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy: Reply to Ghafoor et al. |
Search more.